Cargando…

Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response

Antibody-drug conjugates (ADCs) have emerged as a revolutionary therapeutic class, combining the precise targeting ability of monoclonal antibodies with the potent cytotoxic effects of chemotherapeutics. Notably, ADCs have rapidly advanced in the field of breast cancer treatment. This innovative app...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chang, Hannah L., Schwettmann, Blake, McArthur, Heather L., Chan, Isaac S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10503805/ https://www.ncbi.nlm.nih.gov/pubmed/37712425 http://dx.doi.org/10.1172/JCI172156

Ejemplares similares

The Second Generation Antibody-Drug Conjugate SYD985 Overcomes Resistances to T-DM1
por: Nadal-Serrano, Mercedes, et al.
Publicado: (2020)

Resistance to antibody‐drug conjugates in breast cancer: mechanisms and solutions
por: Chen, Yu‐Fei, et al.
Publicado: (2022)

Immunoregulation by IL-7R-targeting antibody-drug conjugates: overcoming steroid-resistance in cancer and autoimmune disease
por: Yasunaga, Masahiro, et al.
Publicado: (2017)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Mechanisms of Resistance to Antibody-Drug Conjugates
por: Khoury, Rita, et al.
Publicado: (2023)

Polyamine–Drug Conjugates: Do They Boost Drug Activity?
por: Basagni, Filippo, et al.
Publicado: (2023)

Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance
por: Yamazaki, Chisato M., et al.
Publicado: (2021)

Vancomycin Resistance Is Overcome by Conjugation of Polycationic Peptides
por: Umstätter, Florian, et al.
Publicado: (2020)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Antibody–Drug Conjugates for the Treatment of Breast Cancer
por: Corti, Chiara, et al.
Publicado: (2021)

Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates
por: Heater, Natalie K., et al.
Publicado: (2023)

Generation of Antibody-Drug Conjugate Resistant Models
por: Gandullo-Sánchez, Lucía, et al.
Publicado: (2021)

Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates
por: Donaghy, Heather
Publicado: (2016)

Computational selection of antibody-drug conjugate targets for breast cancer
por: Fauteux, François, et al.
Publicado: (2015)

A Danshensu-Tetramethylpyrazine Conjugate DT-010 Overcomes Multidrug Resistance in Human Breast Cancer
por: Zhou, Xinhua, et al.
Publicado: (2019)

Exploration of the antibody–drug conjugate clinical landscape
por: Maecker, Heather, et al.
Publicado: (2023)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Boosting innate immunity in cancer
por: Van Epps, Heather L.
Publicado: (2005)

The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance
por: Retecki, Kuba, et al.
Publicado: (2021)

Novel antibody–drug conjugates for triple negative breast cancer
por: Nagayama, Aiko, et al.
Publicado: (2020)

Antibody-drug conjugates in HER2-positive breast cancer
por: Li, Lixi, et al.
Publicado: (2022)

Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
por: Grinda, Thomas, et al.
Publicado: (2023)

Advances in Targeted Therapy of Breast Cancer with Antibody-Drug Conjugate
por: Subhan, Md Abdus, et al.
Publicado: (2023)

Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer
por: Mulvey, Arthur, et al.
Publicado: (2022)

Antibody-Drug Conjugates in Bladder Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2018)

Resistance and Overcoming Resistance in Breast Cancer
por: Luque-Bolivar, Andrea, et al.
Publicado: (2020)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Doxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cells
por: Łubgan, Dorota, et al.
Publicado: (2008)

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges
por: Guidi, Lorenzo, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in Cancer Therapy—How to Overcome Drug Resistance?
por: Lao, Yefang, et al.
Publicado: (2022)

BioPerine Encapsulated Nanoformulation for Overcoming Drug-Resistant Breast Cancers
por: Pillai, Sindhu C, et al.
Publicado: (2020)

Editorial: Drug resistance in breast cancer – mechanisms and approaches to overcome chemoresistance
por: Raman, Dayanidhi, et al.
Publicado: (2023)

Potential of antibody–drug conjugates and novel therapeutics in breast cancer management
por: Lianos, Georgios D, et al.
Publicado: (2014)

Antibody-Drug Conjugates for the Treatment of HER2-Positive Breast Cancer
por: Najjar, Mariana K., et al.
Publicado: (2022)

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
por: Grinda, Thomas, et al.
Publicado: (2023)

Antibody–Drug Conjugates in Breast Cancer: Current Status and Future Directions
por: Mark, Cynthia, et al.
Publicado: (2023)

Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations
por: D’Arienzo, Andrea, et al.
Publicado: (2023)

Understanding the promising role of antibody drug conjugates in breast and ovarian cancer
por: Babbar, Ritchu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1ghc0ealqi11o3hnjn70hpa2nc